Additionally, autophagy facilitates sorafenib resistance in HCC cells (Liu et al., 2013; Zhai et al., 2014), suggesting that inhibition of autophagy resensitizes HCC cells to sorafenib treatment through blocking the degradation of TARBP2. The gene discussed is TARBP2; the disease is hepatocellular carcinoma.